The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review
MC Frost, H Lampert, JI Tsui, MD Iles-Shih… - Addiction Science & …, 2021 - Springer
Background Methamphetamine/amphetamine use has sharply increased among people
with opioid use disorder (OUD). It is therefore important to understand whether and how use …
with opioid use disorder (OUD). It is therefore important to understand whether and how use …
Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use
MAG Hollander, CCH Chang, AB Douaihy… - Drug and alcohol …, 2021 - Elsevier
Background Despite evidence that individuals with opioid use disorder (OUD) have a lower
risk of mortality when using evidence-based medications for OUD (MOUD), only 20% of …
risk of mortality when using evidence-based medications for OUD (MOUD), only 20% of …
GAWMerge expands GWAS sample size and diversity by combining array-based genotyping and whole-genome sequencing
R Mathur, F Fang, N Gaddis, DB Hancock… - Communications …, 2022 - nature.com
Genome-wide association studies (GWAS) have made impactful discoveries for complex
diseases, often by amassing very large sample sizes. Yet, GWAS of many diseases remain …
diseases, often by amassing very large sample sizes. Yet, GWAS of many diseases remain …
Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder
Background The postpartum year is a vulnerable period for women with opioid use disorder,
with increased rates of fatal and nonfatal overdose; however, data on the continuation of …
with increased rates of fatal and nonfatal overdose; however, data on the continuation of …
Factors associated with 60-day adherence to “safer supply” opioids prescribed under British Columbia's interim clinical guidance for health care providers to support …
M Selfridge, K Card, T Kandler, E Flanagan… - International Journal of …, 2022 - Elsevier
Abstract Aims In March 2020, British Columbia issued Risk Mitigation Guidance (RMG) to
support prescribing of pharmaceutical alternatives to illicit drugs, in order to reduce risk for …
support prescribing of pharmaceutical alternatives to illicit drugs, in order to reduce risk for …
Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
BE Biondi, B Vander Wyk, EF Schlossberg… - Addiction Science & …, 2022 - Springer
Background Medication treatment for opioid use disorder (OUD)(MOUD; buprenorphine and
methadone) reduces opioid use and overdose. Discontinuation of MOUD can quickly lead to …
methadone) reduces opioid use and overdose. Discontinuation of MOUD can quickly lead to …
Trajectories of retention in opioid agonist therapy in a Canadian setting
ME Socías, H Dong, E Wood, R Brar… - International Journal of …, 2020 - Elsevier
Background Long-term engagement in opioid agonist therapy (OAT) has been consistently
associated with reduced risk for morbidity and mortality in people with opioid use disorder …
associated with reduced risk for morbidity and mortality in people with opioid use disorder …
The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review
Background An emerging public health threat of methamphetamine/opioid co-use is
occurring in North America, including increases in overdoses related to concomitant …
occurring in North America, including increases in overdoses related to concomitant …
Predictors of opioid and alcohol pharmacotherapy initiation at hospital discharge among patients seen by an inpatient addiction consult service
Background: Medications for opioid use disorder (MOUD) and alcohol use disorder (MAUD)
are effective and under-prescribed. Hospital-based addiction consult services can engage …
are effective and under-prescribed. Hospital-based addiction consult services can engage …